NCT01791686

Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease

A Pilot, Open-label, Multicenter Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Celldex Therapeutics · Industry
• Sex: All
• Age: 4 Years
• Healthy volunteers: Not accepted

Summary

This study is evaluating the study drug (CDX-1135) in patients with dense deposit disease (DDD). The objective is to evaluate the safety and activity of repeated doses of CDX-1135 in pediatric and adult patients with DDD. After screening, eligible patients will be entered into the Induction Period. The Induction Period is up to 4 weeks. Following normalization of complement activity, patients will enter into the Maintenance Period.The total treatment duration is up to 26 weeks.

Conditions

• Dense Deposit Disease
• Membranoproliferative Glomerulonephritis Type II
• C3 Glomerulonephritis

Interventions

Type	Name	Description
DRUG	CDX-1135

Timeline

• Start date: 2013-01-01
• Primary completion: 2014-03-01
• Completion: 2014-03-01
• First posted: 2013-02-15
• Last updated: 2014-03-07

Locations

1 site across 1 country: United States